Kornimate/medical-research-clean huggingface dataset:
monitoring of non-invasive ventilation during sleep in als

Conditions: Amyotrophic Lateral Sclerosis

Summary: non-invasive ventilation (niv) has already shown to improve survival and quality of life in patients with amyotrophic lateral sclerosis (als). quality of sleep seems already to be impaired in patients with preserved diaphragmatic dysfunction. until now, only few research has been performed on the quality of sleep in patients with als when using niv, and these data are mainly based on patient reported outcomes.further on, only very little research has been done on patient-ventilator interaction. our study would like to perform research on quality of sleep before and after niv use by using full polysomnography with incorporation of transcutaneous carbon dioxide measurement and built-in ventilator software.


Eligibility criteria:
inclusion criteria: * patients with als (according to el escorial criteria) who are planned to start to use niv, objectivated by a decreased inspiratory muscle force with a restrictive pulmonary function and 1. symptoms of nocturnal alveolar hypoventilation or 2. increased daytime arterial carbon dioxide partial pressure (pco2)(\> 45 mmhg) or 3. a ≥ 10 mmhg increase in transcutaneous pco2 during sleep in comparison to a normal awake supine value exclusion criteria: * patients \< 18 years * patients not willing to start niv

Keywords: amyotrophic lateral sclerosis noninvasive ventilation polysomnography
long-term study of efficacy/safety of adapalene/benzoyl peroxide topical gel in acne vulgaris subjects

Conditions: Acne Vulgaris

Summary: this was a multi-center, open-label, non-comparative study that evaluated the long-term safety and efficacy profile of adapalene/benzoyl peroxide gel. subjects were evaluated at baseline, weeks 1 and 2, and months 1, 2, 4, 6, 8, 10, and 12. safety was evaluated by spontaneous reports of adverse events (aes), the local tolerability assessment (erythema, scaling, dryness, and stinging/burning), routine laboratory testing (hematology, blood chemistry, and urinalysis), and monitoring of suspected sensitizations. efficacy was evaluated by analysis of percent change from baseline in inflammatory, noninflammatory, and total lesion counts, and by the subject's assessment of acne.


Eligibility criteria:
inclusion criteria: * a clinical diagnosis of acne vulgaris with facial involvement. * a minimum of 20 but not more than 50 inflammatory lesions. * a minimum of 30 but not more than 100 noninflammatory lesions. exclusion criteria: * subjects with presence of nodules or cysts. * acne conglobate, acne fulminans, secondary acne, or severe acne. * underlying diseases that required the use of interfering topical or systemic therapy. * use of prohibited medications prior to the study unless appropriate washout period was documented.

Keywords: acne vulgaris adapalene benzoyl peroxide
narval cc mandibular repositioning device in the second-line treatment of severe obstructive sleep apnea hypopnea (osah)

Conditions: Obstructive Sleep Apnea Syndrome

Summary: the purpose of this study is to evaluate the long-term efficacy, tolerance and compliance of orm narval mandibular repositioning device (mrd) as a second-line treatment for patients with severe obstructive sleep apnea hypopnea (osah) syndrome who refuse or are intolerant to continuous positive airway pressure (cpap) treatment.

osah is a common condition which occurs in between 1 and 4% of the adult population. respiratory obstruction may be complete (apnea) or incomplete (hypopnea). this disorder disturbs the architecture and quality of sleep, and is a known risk factor in the development of cardiovascular and metabolic diseases. cpap is the standard treatment, however in some cases patients are unable to use it (rejection, intolerance, etc.). in such circumstances, treatment using a mrd may result in an improvement of symptoms. very few long-term clinical data are available on treatment of osah by mrd. this study should allow to have a precise and representative vision of 5 years results of orm narval mrd treatment in conditions of good practices (titration, controls of efficacy).

Eligibility criteria:
inclusion criteria: * adult patient with severe osah (ahi \> 30 or ahi of between 5 and 30 along with severe daytime sleepiness), * intolerant to or having refused cpap therapy, * no dental, parodontal or articulatory contraindications, * no experience of any mandibular advancement device therapy, * medical insurance. exclusion criteria: * severe psychiatric disorders or severe neuromuscular disorders * \> 20% of central apneas during the baseline assessment, * severe osah with an ahi \> 30 associated with another sleep pathology (narcolepsy with or without cataplexy, idiopathic hypersomnia, severe restless legs syndrome), * pregnant or breastfeeding woman, * informed consent not signed, * patient requiring special protection such as patients with appointed guardians and patients without legal or administrative rights, * patient who is completely or partially edentulous

Keywords: mrd narval oral appliance obstructive sleep apnea osah osa treatment
4hz transcranial alternating current stimulation for patients with mild alzheimer's disease

Conditions: Alzheimer Disease

Summary: the goal of this study is to explore the efficacy and safety of 4hz transcranial alternating current stimulation (tacs) in patients with mild alzheimer's disease (ad). the study will recruit 40 individuals with mild ad, and the participants will be randomized to either a 4 hz tacs group or a sham stimulation group. both groups will undergo 30 one-hour sessions across 3 weeks (21 days). at the end of the intervention and 3-month follow-up, all subjects will repeat the baseline assessments.

background: recently, transcranial alternating current stimulation (tacs), which could interact with ongoing neuronal activity, has emerged as a potentially effective and promising treatment for alzheimer's disease (ad), and the 4hz frequency was suggested to improve working memory methods: the proposed study is a double-blinded, randomized controlled trial that will include 40 individuals with mild ad, and the participants will be randomized to either a 4hz tacs group or a sham stimulation group. both groups will undergo 30 one-hour sessions in 3 weeks (21 days). the outcome measures will be assessed at baseline, end of intervention and 3 months after the first session. primary outcome is global cognitive function, assessed by the 11-item cognitive subscale of the alzheimer's disease assessment scale (adas-cog), and the second outcomes include changes in other neuropsychological assessments, structural mri, resting electroencephalogram (eeg) and simultaneous eeg-functional mri (fmri).

Eligibility criteria:
inclusion criteria: 1. subjects with informed consent; 2. 45-75 years of age; 3. at least 6 years of education; 4. ad according to the national institute on aging and the alzheimer's association (nia-aa) guidelines; 5. clinical dementia rating scale (cdr)=1.0; 6. positive findings in amyloid pet imaging or amyloid protein levels in csf; 7. on a stable dose of cholinesterase inhibitors (e.g. donepezil or rivastigmine) as defined as 6 consecutive weeks of treatment at an unchanging dose, and without any intentions to modify the dosage during the observation period. exclusion criteria: 1. current or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis), poorly controlled migraines or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment; 2. contraindication for undergoing mri or receiving tacs; 3. eczema or sensitive skin; 4. familial ad; 5. depression or other psychiatric disorders; 6. abnormal brain structural magnetic resonance imaging (mri) scan, including hydrocephalus, stroke, structural lesions, etc. that would potentially confound the outcome; 7. severe cardiovascular/pulmonary disorders; 8. other conditions, in the investigator's opinion, might not be suitable for the study.
the role of ctdna in predicting the recurrence risk of colorectal cancer

Conditions: Colorectal Cancer Stage II; Colorectal Cancer Stage III

Summary: the purpose of this study was to observe the relationship between ctdna as a molecular marker of colorectal cancer and the risk of postoperative recurrence.

in this clinical study, ctdna will be detected in postoperative patients with stage ⅱ and ⅲ colorectal cancer to evaluate the correlation between ctdna and the risk of postoperative recurrence. according to the dynamic changes of ctdna after adjuvant chemotherapy, the correlation between ctdna and postoperative dfs will be compared, and the feasibility of ctdna as a molecular marker to evaluate the risk of postoperative recurrence of colorectal cancer will be investigated.

Eligibility criteria:
inclusion criteria: * 1. patients with colorectal cancer diagnosed pathologically as stage ⅱ and stage ⅲ. * 2. the patient underwent radical surgical treatment. * 3. the patient has the results of genetic genetic testing for gastrointestinal tumors, including the genetic mutation status of mmr genes and related genes (mlh1, msh2, msh6, pms2, mlh3, epcam). * 4. the patient understands and is willing to sign a written informed consent document. * 5. during the treatment process, the patient can cooperate to provide samples of each node. * 6. the patient can provide corresponding clinical materials, including but not limited to case diagnosis, imaging evaluation, and serum protein marker test results. exclusion criteria: * 1. the patient cannot provide a complete and qualified specimen. * 2. the patient has other primary malignant tumors or serious medical illnesses. * 3. the patient cannot cooperate with the follow-up. * 4. conditions that other researchers deemed inappropriate for continuing to participate in the study.

Keywords: ctdna adjuvant chemotherapy colorectal cancer
study to assess hypoallergenicity of a new amino-acid based infant formula in children with cow's milk allergy

Conditions: Cow's Milk Allergy

Summary: this is a prospective, controlled, multi-country study to verifying the hypoallergenicity of the new amino acid-based formula in infants and children aged\< 12 years with documented cow's milk protein allergy (cmpa).

not provided

Eligibility criteria:
inclusion criteria: * children with documented cow's milk allergy, confirmed by one of the following criteria, within six months prior to study start (visit 2): * positive double-blind, placebo-controlled oral food challenge (dbpcfc) with cow's milk or * positive open or single-blind oral food challenge with cow's milk carried out under the supervision of a specialist in children with clear immediate reactions and a positive test for specific ige (in serum \[sige\>0,35 kui/l\] or skin prick test \[spt ≥ 3 mm\]) or * reported convincing allergic symptoms following an exposure to milk or a milk-containing food product and detectable serum milk-specific ige or positive skin prick test * aged ≤12 years of age at screening. * expected consumption of a minimum of 250ml of study formula per day during the open challenge. * written informed consent from one or both parents (depending on the local legislation) or legal representative. exclusion criteria: * children who receive breastfeeding at study enrolment. * had any chronic medical diseases, chromosomal or major congenital anomalies, or major gastrointestinal disease/abnormalities (other the cmpa); had immunodeficiency; antihistamine \[excluding eye drops\] use in 7 days prior to a food challenge or oral steroid use within 14 days prior to enrolment; unstable asthma; severe uncontrolled eczema; * severe anaphylactic reaction \[required ≥ 2 doses of epinephrine\] to milk or breast milk within the past 2 years; * existing illness that could interfere with formula acceptance or identification of allergic reactions. * investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements. * participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.
long term safety observation of crizotinib in chinese nsclc population

Conditions: ALK or ROS1-positive NSCLC

Summary: this study is to allow access to crizotinib who were treated in previous pfizer-sponsored studies in china.

this study is a phase 4 study, to continually access xalkori to chinese patients who were recruited in previous studies of crizotinib in china, and only collect the safety data.

Eligibility criteria:
inclusion criteria: 1. patients who were enrolled and treated in studies a8081005, a8081007, a8081014, a8081029, or a8081063 and are still receiving crizotinib treatment at the time of enrollment into this study. or patients randomized to the chemotherapy arm in studies a8081014 or a8081029 who have experienced investigator assessed disease progression and have not yet crossed over to receive crizotinib treatment. 2. no ongoing nci ctcae grade 3 or intolerable grade 2 adverse events considered to be related to crizotinib treatment 3. eastern cooperative oncology group (ecog) performance status 0-3 4. adequate organ function as defined by the following criteria exclusion criteria: 1. use of any anticancer drug subsequent to crizotinib prior to study entry 2. use of drugs or foods that are known potent cytochrome p450 (cyp)3a4 inhibitors 3. use of drugs that are known potent cyp3a4 inducers 4. concurrent use of drugs that are cyp3a4 substrates with narrow therapeutic indices, associated with life threatening arrhythmias

Keywords: nsclc
a trial of custom foot orthoses for the treatment of plantar heel pain

Conditions: Plantar Fasciitis

Summary: this is a study investigating treatment of plantar fasciitis (heel pain). physicians commonly prescribe specialized orthoses (shoe inserts) to treat heel pain. this study will evaluate the reduction in heel pain associated with three types of orthoses. it is hypothesized that custom made orthoses will significantly decrease pain and improve foot function in comparison to prefabricated insoles and sham insoles.


Eligibility criteria:
inclusion criteria: patients will be included if they present for each of the following: * pain at plantar fascial attachment to calcaneal tubercle and/or pain distal from tubercle along plantar fascial band * typical post-static dyskinesia. pain first steps in morning or when getting up after being seated for a period of time * patients will be ambulatory with an age range of 18-75 with plantar heel pain present for no more than one year. * they will not have previous injection within 6 months or currently use prescription custom foot orthoses. * patient history, exam, x-rays, and ultrasound will rule out other etiologies of heel pain including proximal or local nerve entrapment, arthritis, bone cyst or tumor, or stress fracture. since most patients will likely self-treat this condition prior to seeking care, the investigators will allow a washout period (appendix) and acetaminophen rescue analgesia provision. exclusion criteria: * proximal musculoskeletal pathology (i.e., knee or hip arthritis, sciatica secondary to back pathology, significant limb length discrepancy. * use of gait assistive devices (crutches, canes, walkers). * inability to wear supportive closed toed shoes. * lack of range motion at the first metatarsophalangeal joint or subtalar joint.

Keywords: heel pain
the acute effect of cervical mobilization in parkinson's disease

Conditions: Idiopathic Parkinson's Disease

Summary: patients with idiopathic parkinson's disease have balance and gait problems due to sensory and motor impairments. in the literature, there are lots of studies including various approaches for rehabilitation of these parameters such as sensory interventions, conservative treatments, neurophysiological approaches and motor imagery. however, taking into account of literature, there is no study investigating the effects on balance and gait of cervical mobilization by stimulating proprioceptors and vestibular receptors. therefore, the aim of this study is to investigate the acute effect of cervical mobilization on balance and gait in patients with idiopathic parkinson's disease.

patients with idiopathic parkinson's disease have balance and gait problems due to sensory and motor impairments. in the literature, there are lots of studies including various approaches for rehabilitation of these parameters such as sensory interventions, conservative treatments, neurophysiological approaches and motor imagery. the posture of the cervical region is impaired by the findings of the disease such as rigidity, flexor posture and loss of axial rotation. considering that the cervical region is rich in proprioceptors and one of the key points for the vestibular system, interventions to this area can be thought to contribute to postural control and gait. however, taking into account of literature, there is no study investigating the effects on balance and gait of cervical mobilization by stimulating proprioceptors and vestibular receptors. therefore, the aim of this study is to investigate the acute effect of cervical mobilization on balance and gait in patients with idiopathic parkinson's disease.

Eligibility criteria:
inclusion criteria: * having been diagnosed with idiopathic parkinson's disease * being between the ages of 50-80 * patients scoring \>24 on standardized mini mental state examination * modified hoehn and yahr stage 2-3 * no medication or dose changes during treatment * not participating in the physiotherapy and rehabilitation program in the last 6 months * volunteering to participate in the study exclusion criteria: * vertebrobasilar insufficiency * other neurological diseases * postural hypotension, visual problems (which can not be compensated with the correct lens) or vestibular disorders that may affect balance * cardiopulmonary diseases that may affect gait * orthopedic problems (such as fracture, osteomyelitis, severe osteoporosis), advanced inflammatory arthritis, knee prothesis * uncontrolled dyskinesia or motor fluctuation * excessive use of alcohol or substance abuse * anticoagulant therapy, blood clotting diseases * long-term use of corticosteroids

Keywords: parkinson's disease cervical spine postural balance gait manual therapies
the effect of ischaemic-reperfusion and ischaemic preconditioning on the endogenous fibrinolysis in man

Conditions: Ischaemic Heart Diseases

Summary: heart attacks are usually caused by a blood clot blocking an artery supplying blood to the heart. current treatments are designed at relieving this blockage as quickly as possible to minimise damage to the heart muscle. however in restoring the supply of blood local damage known as "ischaemia-reperfusion injury" may occur. the aim of this study is to assess how clot forming and clot dissolving pathways are affected during this process, and examine the role of a natural inflammatory hormone, bradykinin. this will help us to understand the mechanism by which ischaemia-reperfusion injury may occur and to devise new treatments for heart attacks.


Eligibility criteria:
inclusion criteria: * healthy males between 18-65 years of ages, non-smokers. exclusion criteria: * any concurrent illness or chronic medical condition. concurrent use of vasoactive medication. smoking history.

Keywords: ischaemia reperfusion t-pa fibrinolysis endothelial function local and remote ischaemic preconditioning
a retrospective cohort study: influence of mthfr c677t and a1298c polymorphisms on the survival of pediatric patients with non-hodgkin's lymphoma

Conditions: Pediatric Non-Hodgkin Lymphoma

Summary: the primary purpose of this retrospective study was to investigate the influence of methylenetetrahydrofolate reductase (mthfr) c677t/a1298c polymorphism on the survival of pediatric patients with non-hodgkin lymphoma (nhl) treated with modified nhl-bfm95 protocol in south china.


Eligibility criteria:
inclusion criteria: 1. aged ≤ 18 years; 2. newly diagnosed as the four main categories of nhl(burkitt's lymphoma, lymphoblastic lymphoma, anaplastic large cell lymphoma, and diffuse large b-cell lymphoma) between 2014 and 2020; 3. treated according to the modified bfm95 protocol. exclusion criteria: 1. aged \> 18 years; 2. not newly diagnosed as the four main categories of nhl between 2014 and 2020; 3. treated according to chemotherapeutic regimens except for the modified bfm95 protocol.

Keywords: mthfr c677t polymorphism；a1298c; pediatric non-hodgkin lymphoma；survival.
brain injury inpatient educational intervention for families and caregivers

Conditions: Traumatic Brain Injury; Acquired Brain Injury

Summary: the brain injury inpatient guide for families and caregivers (biig-facs) is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute, inpatient brain injury rehabilitation.

the brain injury inpatient guide for families and caregivers (biig-facs), developed by j. niemeier and j. kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation. program development was guided by considerable clinical experience, research review, and solicited consumer feedback. the intervention has been manualized to facilitate efficient and effective administration. now, a rigorous investigation involving randomized assignment to treatment and control groups is needed to empirically examine outcomes. helping family members to cope more effectively has the potential to improve outcomes for persons with abi. strengthening families can enable persons with abi to live more independently, achieve greater community integration, and live healthier lives. the investigation serves as a logical next step forward in advancing our understanding of standardized interventions designed to serve the family unit.

Eligibility criteria:
inclusion criteria: * family members/caregiver friends of patients with abi will be eligible to participate in the present investigation. abi is defined as damage to brain tissue caused by stroke, aneurysm, anoxia, non-progressive brain tumor, infection, or an external mechanical force as evidenced by: loss of consciousness, post traumatic amnesia (pta), objective neurological findings, or skull fracture. * lacerations and/or bruises of the scalp or forehead without other criteria listed above will be excluded. * all family member participants and patients must be at least 18 years of age or older and able to understand and provide consent (or assent in the case of the patients). exclusion criteria: * family members at imminent risk of psychiatric hospitalization, or in imminent danger of hurting themselves or others, as judged by the investigators, will be excluded from the study.

Keywords: brain injury family treatment